Weber Christophe Pierre 4
4 · BOSTON SCIENTIFIC CORP · Filed May 11, 2026
Research Summary
AI-generated summary of this filing
Boston Scientific (BSX) Director Christophe Weber Receives Awards
What Happened Christophe Weber, a director of Boston Scientific Corporation (BSX), received equity awards on 2026-05-07 totaling 5,567 shares/units: 1,767 restricted shares (award), 1,140 restricted shares (award), and 2,660 deferred stock units (derivative award). All awards are reported at $0.00 per share because they were grants (not open-market purchases) and together reflect an approximate aggregate value of $315,000 based on the company’s stated valuations.
Key Details
- Transaction date: 2026-05-07; Filing date: 2026-05-11 (filed 4 days after the transaction, which is longer than the standard two-business-day Form 4 deadline).
- Reported transaction codes: A = Award/Grant (no cash purchase or sale).
- Share counts: 1,767 RSUs (F1), 1,140 RSUs (F2), 2,660 deferred stock units (F3/F4) — total 5,567.
- Price reported: $0.00 per share (awards/grants).
- Shares owned after transaction: Not disclosed in the provided filing excerpt.
- Notable footnotes:
- F1: 1,767 restricted shares granted in lieu of 80% of annual cash retainer (~$100,000).
- F2: 1,140 restricted shares from 30% portion of the annual equity award (~$64,500).
- F3/F4: 2,660 deferred stock units (each represents one share to be issued later); F4 notes these units vest at the next annual meeting and will be issued following separation from board service. The deferred portion reflects ~$150,500 (70% of the $215,000 annual equity award).
- Filing timeliness: The filing appears to have been submitted later than the typical two-business-day requirement.
Context These entries are compensation awards for a non-employee director (part of the director compensation program) and are not open-market purchases or sales; they do not by themselves indicate personal buying/selling sentiment. The deferred stock units are a promise to issue shares later (per the company’s Deferred Compensation Plan) and are treated as derivative awards until converted.
Insider Transaction Report
- Award
Common Stock
[F1]2026-05-07+1,767→ 2,646 total - Award
Common Stock
[F2]2026-05-07+1,140→ 3,786 total - Award
Deferred Stock Units
[F3][F4]2026-05-07+2,660→ 2,660 total→ Common Stock (2,660 underlying)
Footnotes (4)
- [F1]Grant of restricted stock in lieu of 80% yearly cash compensation, vesting in full upon the next annual meeting of stockholders. Reflects a value of approximately $100,000 (representing 80% of the amount of the non-employee director compensation program's cash retainer having a value of $125,000) divided by the closing price of the common stock on the date of grant.
- [F2]Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant. Reflects a value of $64,500 (representing 30% of the amount of the non-employee director compensation program's annual equity award having a value of $215,000) divided by the closing price of common stock on the date of grant.
- [F3]Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
- [F4]Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $150,500 (representing 70% of the non-employee director compensation program's annual equity award having a value of $215,000) divided by the closing price of common stock on the date of grant.